anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Whipple's disease, an extremely rare, chronic infection caused by Tropheryma whipplei, an actinobacterium ubiquitously present in the environment, is a multisystemic condition that can affect several organs. Therefore, Whipple's disease should always be considered by physicians working across various branches of medicine, including internal medicine, rheumatology, infectious diseases, gastroenterology, haematology, and neurology. Initially, Whipple's disease is challenging to diagnose due to both its rarity and non-specific clinical features, almost indistinguishable from rheumatological conditions. A few years later, the onset of gastrointestinal symptoms increases the specificity of its clinical picture and helps in reaching the correct diagnosis. Diagnosis is typically made by finding PAS-positive macrophages in the lamina propria at duodenal biopsy. PCR for Tropheryma whipplei is nowadays also increasingly available, and represents an undeniable help in diagnosing this condition. However, it may also be misleading as false positives can occur. If not promptly recognized and treated, central nervous system involvement may develop, which can be fatal. The therapeutic gold standard has not yet been fully established, particularly in cases of recurrent disease, neurological involvement, and an immune reconstitution inflammatory syndrome that may arise following the initiation of antibiotic therapy.
PURPOSE: To produce a beauty culture article for beauty culture of whole body, utilizing a natural component, by noticing component characteristics, which bean-curd refuse has, smoothing skin keratin and skin spot removing effect which wheat periderm, namely bran has. CONSTITUTION: An alkali substance of bean-curd refuse is neutralized. The bean-curd refuse is mixed with about 30% of wheat periderm having skin spot removing effect, namely bran with suppressing the alkali substance, incorporated with purified water, heated, blended with a small amount of lactic acid and preserved at normal temperature. The mixture is isolated from influence of the open air and stabilized for many hours in a primary fermentation state. The bran neutralizes the alkali substance having bad influence on skin in the bean-curd refuse and compensates the defect of the bean-curd refuse by blending with the bean-curd refuse. The bran itself forms kojic acid by the mixing and exhibits skin spot removing effect. As the final process, perfume is added to the mixture, which is packed in vacuum so as to keep an article in a stable state until it is used.
BACKGROUND: Studies in general population reported a positive association between tobacco smoking and airflow obstruction (AFO), a hallmark of chronic obstructive pulmonary disease (COPD). However, this attempt was less addressed in silica dust-exposed workers.
METHODS: This retrospective cohort study consisted of 4481 silicotic workers attending the Pneumoconiosis Clinic during 1981-2019. The lifelong work history and smoking habits of these workers were extracted from medical records. Spirometry was carried out at the diagnosis of silicosis (n = 4177) and reperformed after an average of 9.4 years of follow-up (n = 2648). AFO was defined as forced expiratory volume in one second (FEV1)/force vital capacity (FVC) less than lower limit of normal (LLN). The association of AFO with smoking status was determined using multivariate logistics regression, and the effect of smoking cessation on the development of AFO was evaluated Cox regression.
RESULTS: Smoking was significantly associated with AFO (current smokers: OR = 1.92, 95% CI 1.51-2.44; former smokers: OR = 2.09, 95% CI 1.65-2.66). The risk of AFO significantly increased in the first 3 years of quitting smoking (OR = 1.23, 95% CI 1.02-1.47) but decreased afterwards with increasing years of cessation. Smoking cessation reduced the risk of developing AFO no matter before or after the confirmation of silicosis (pre-silicosis cessation: HR = 0.58, 95% CI 0.46-0.74; post-silicosis cessation: HR = 0.62, 95% CI 0.48-0.79).
CONCLUSIONS: Smoking cessation significantly reduced the risk of AFO in the workers with silicosis, although the health benefit was not observed until 3 years of abstinence. These findings highlight the importance of early and long-term smoking cessation among silicotic or silica dust-exposed workers.
PURPOSE: Optimization of medical factors including diabetes and obesity is a cornerstone in the prevention of prosthetic joint infection (PJI). Dyslipidaemia is another component of metabolic syndrome which has not been thoroughly investigated as an individual, modifiable risk factor. This study examined the association of dyslipidaemia with PJI caused by the lipophilic microbe Cutibacterium acnes (C. acnes).
METHODS: A retrospective chart review examined patients with positive C. acnes culture at hip or knee arthroplasty explantation. A control group with methicillin-sensitive Staphylococcus aureus (MSSA) positive cultures at explantation was matched for age, sex, and surgical site, as well as a second control group with no infection. A total of 80 patients were included, 16 with C. acnes, 32 with MSSA, and 32 with no infection. All patients had a lipid panel performed within one year of surgery. Lipid values and categories were compared using multinomial logistic regressions.
RESULTS: High or borderline triglycerides (TG) (relative risk ratio (RRR) = 0.13; P = 0.013) and low high-density lipoprotein (HDL) (RRR = 0.13; P = 0.025) were significantly associated with C. acnes PJI compared to MSSA-PJI. High or borderline TG (RRR = 0.21; P = 0.041) and low HDL (RRR = 0.17; P = 0.043) were also associated with a greater probability of C. acnes infection compared to no infection.
CONCLUSIONS: The presence of elevated TG and low HDL were both associated at a statistically significant level with C. acnes hip or knee PJI compared to controls with either MSSA PJI or no infection. This may represent a specific risk factor for C. acnes PJI that is modifiable.
Patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administrated at the standard dose of 100ug.
Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult female subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 12 and 14.
There are 10 practices within the Carolinas Healthcare System (CHS) network that have already received additional training for improving outcomes for patients with chronic diseases termed the Integrated Approach to Care (IAC). This IAC approach developed by CHS is based on the Chronic Care Model (CCM). The IAC approach includes a heavy emphasis on the use of health information technology that practices receive during the initial EAP rollout.
Implementation of quality improvement initiative to utilize RPM in PP HDP. Patients will utilize remote monitoring technology and bluetooth enabled BP buff to self monitor BPs- autopopulate to provider portal, and then have a telemedicine appointment at 48 hours post hospital discharge.
Serious drug-induced liver injury (DILI), including liver transplantation and death, have been reported postmarketing with fenofibric acid. DILI has been reported within the first few weeks of treatment or after several months of therapy and in some cases has reversed with discontinuation of fenofibric acid delayed-release capsules treatment. Patients with DILI have experienced signs and symptoms including dark urine, abnormal stool, jaundice, malaise, abdominal pain, myalgia, weight loss, pruritus, and nausea. Many patients had concurrent elevations of total bilirubin, serum alanine transaminase (ALT), and aspartate transaminase (AST). DILI has been characterized as hepatocellular, chronic active, and cholestatic hepatitis, and cirrhosis has occurred in association with chronic active hepatitis.

In clinical trials, fenofibric acid delayed-release capsules at a dose of 135 mg daily has been associated with increases in serum AST or ALT. The incidence of increases in transaminases observed with fenofibrate therapy may be dose related [see Adverse Reactions (6.1)].

Fenofibric acid delayed-release capsules is contraindicated in patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Contraindications (4)]. Monitor patient's liver function, including serum ALT, AST, and total bilirubin, at baseline and periodically for the duration of therapy with fenofibric acid. Discontinue fenofibric acid delayed-release capsules if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST > 3 times the upper limit of normal, or if accompanied by elevation of bilirubin). Do not restart fenofibric acid delayed-release capsules in these patients if there is no alternative explanation for the liver injury.
Foeniculum vulgare Mill. is a medicinal and food homologous plant, and it has various biological activities. Yet, no research has explored its anti-motion sickness effects. Chemical properties of fennel extracts (FvE) and flavonoids (Fvf) were analyzed based on UPLC-QTRAP-MS to elucidate its potential anti-motion sickness components in the present study. The mice models of motion sickness were stimulated by biaxial rotational acceleration. Behavioral experiments such as motion sickness index and open field test and the measurement of neurotransmitters were used to evaluate the efficacy of compounds on motion sickness. Results showed that FvE contains terpenes, alkaloids, flavonoids, etc. Eight flavonoids including quercetin-3β-D-glucoside, rutin, hyperoside, quercetin, miquelianin, trifolin, isorhamnetin and kaempferol were identified in the purified Fvf. FvE and Fvf significantly reduced the motion sickness index of mice by 53.2% and 48.9%, respectively. Fvf also significantly alleviated the anxious behavior of mice after rotational stimulation. Among the eight flavonoids, isorhamnetin had the highest oral bioavailability and moderate drug-likeness index and thus speculated to be the bioactive compound in fennel for its anti-motion sickness effect. It reduced the release of 5-HT and Ach to alleviate the motion sickness response and improve the work completing ability of mice and nervous system dysfunction after rotational stimulation. This study provided in-depth understanding of the anti-motion sickness bioactive chemical properties of fennel and its flavonoids, which will contribute to the new development and utilization of fennel.
This study investigated factors associated with cognitive performance among Black caregivers of persons living with two chronic conditions: dementia or cancer. Fifty-six Black caregivers of people living with dementia or cancer were recruited from clinic and community sources. Variables measured included: depression, anxiety, stress, sleep, fatigue, and caregiver burden. Cognitive performance was assessed using the Montreal Cognitive Assessment (MoCA). Descriptive statistics and non-parametric analyses were conducted to identify factors related to MoCA scores. Caregivers were 58.3 years of age and predominantly female. The average MoCA score was 25.23. Gender and education, along with positive appraisal of caregiving were significantly associated with cognitive performance. Several other factors approached significance including cohabitation with the care recipient, fatigue, and stress due to perceived individual and institutional racism. Our findings suggest several factors that warrant further investigation for understanding the relationship between caregiving and cognitive performance in Black caregivers of people living with cancer or dementia.
The invention provides for a nasal spray which is an aqueous solution containing a broad spectrum microbicide which may be applied in nasal passages in the manner of a decongestant type nose spray in the event of known or suspected exposure of the individual to common cold virus, flu, or other infective microbial agents. The solution contains active agents which are based on a chlorine or hypochlorite solution, or a solution of chlorine or hypochlorite plus a salt of chloride, bromide or iodide. Alternatively, the solution may contain a bromine solution, or a solution of bromine plus a salt of chloride, bromide or iodide such as sodium chloride, zinc chloride, sodium bromide, zinc bromide, sodium iodide or zinc iodide. The chlorine, hypochlorite, bromine, chloride, bromide, and iodide may originally come from inorganic compounds or organic compounds, which are then dissolved in the water. Further, the solution may contain glycerin or another moisturizing or wetting agent for the nasal mucosa. Zinc gluconate or a zinc halide such as zinc chloride, zinc bromide or zinc iodide may also be included.
Dosing errors can result in accidental overdose and death. Avoid dosing errors that may result from confusion between mg and mL and confusion with codeine and promethazine solutions of different concentrations, when prescribing, dispensing, and administering Promethazine HCl, Phenylephrine HCl and Codeine Phosphate Oral Solution. Ensure that the dose is communicated clearly and dispensed accurately [see Dosage and Administration (2.1)]. 

Instruct patients and caregivers on how to measure and take or administer the correct dose of Promethazine HCl, Phenylephrine HCl and Codeine Phosphate Oral Solutionand to use extreme caution when measuring the dose. Strongly advise patients to obtain and always use a graduated device that can measure and deliver the prescribed dose accurately, and to never use household teaspoons or tablespoons to measure a dose because these are not accurate measuring devices. For prescriptions where a measuring device is not provided, a pharmacist can provide an appropriate calibrated measuring device and can provide instructions for measuring the correct dose.
A ringworm vaccine is disclosed comprising antigen isolated from at least one dermatophyte and a suitable carrier. The “antigen” can include a single antigen from a dermatophyte or a plurality of antigens as long as at least one antigen is included which will produce a sufficient immune response to confer resistance to ringworm infection upon the recipient of the vaccine. The antigen can also be isolated from more than one dermatophyte. If a preparation from more than one dermatophyte is made the antigen can include antigens which are common to all species of dermatophytes employed and/or antigens which are only specific to certain species. A method of producing such a ringworm vaccine is also disclosed. The method comprises making an antigen preparation comprising the dermatophyte antigen described above and combining the antigen preparation with a suitable carrier. Methods of treating a patient are also disclosed employing the vaccine of the present invention and vaccines produced according to the method of the present invention. Methods are also disclosed for treating a pregnant patient with such vaccines such that the progeny of the pregnancy exhibit resistance to ringworm infection at birth.
Patients randomized to the dual shock group will have two near-simultaneous 200-Joule shocks delivered through the two sets of pads (antero-posterior position and right infraclavicular-axillary position). The first of these shocks will be synchronized.
PURPOSE: The aim of this study was to characterize antibiotic prophylaxis practices in pediatric patients who have received posterior arthrodesis for spinal deformity and understand how these practices impact 30-day postoperative infection rates.
METHODS: This was a retrospective cohort study using the National Surgical Quality Improvement Program Pediatric database for year 2021. Patients 18 years of age or younger who received posterior arthrodesis for scoliosis or kyphosis correction were included. The outcome of interest was 30-day postoperative infection. Fisher's exact test and multivariable regression analysis were used to analyze the impact of intravenous antibiotic prophylaxis, intraoperative intravenous antibiotic redosing after 4 h, postoperative antibiotic prophylaxis, intraoperative topical antibiotics on 30-day postoperative infection, and various antibiotic prophylaxis regimens.
RESULTS: A total of 6974 patients were included in this study. The 30-day infection rate was 2.9%. Presurgical intravenous antibiotic (11.5% vs. 2.7%, p = 0.005), postoperative antibiotic (5.7% vs. 2.4%, p < 0.01), and intraoperative topical antibiotic (4.0% vs. 2.7%, p = 0.019) were associated with significantly reduced infection rates. There was no significant difference in infection rates between patients that received cefazolin versus vancomycin versus clindamycin. The addition of Gram-negative coverage did not result in significant differences in infection rates. Multivariable regression analysis found postoperative intravenous antibiotics and intraoperative topical antibiotics to reduce infection rates.
CONCLUSIONS: We found the use of presurgical intravenous antibiotics, postoperative intravenous antibiotics, and intraoperative topical antibiotics to significantly reduce infection rates. Results from this study can be applied to future research on implementation of standardized infection prevention protocols.
LEVEL OF EVIDENCE: Level II.
A local reaction characterized by erythema and edema that persists for several hours or longer, or a recurrence of allergic symptoms following an injection requires that the dosage be reduced. Additional extract should not be given until all evidence of a previous reaction has disappeared.   
Severe generalized symptoms or anaphylaxis following an injection must be treated immediately with epinephrine HCL 1:1000 as follows: Usual Dosage - Children under 12 years 0.1 to 0.2 cc; persons over 12 years 0.3 to 0.5 cc, repeated as necessary every 10 to 15 minutes. Intravenous antihistamines and hydro-cortisone also may be used, but only after sufficient epinephrine has been give. (see Adverse Reaction Systemic).   
Immunotherapy after anaphylaxis should only be considered if the probable cause of anaphylaxis can be identified, such as accidental intravenous injection or failure to reduce the dosage after a previous local reaction or during periods of high external exposure to ragweed pollen.
Recombinant polynucleotide that contains a plurality of first polynucleotides encoding an antigenic peptide are provided by this invention. The first polynucleotides are operatively linked to each other to enhance translation of the polynucleotides to the antigenic peptide and binding of the antigenic peptide to MHC molecules. In a further embodiment, the recombinant contains a plurality of a second polynucleotide encoding multiple copies of antigenic peptides having an amino acid sequence that is different from the peptides encoded by the first polynucleotides. The polynucleotides are useful as cancer vaccines or in adoptive immunotherapy. In these embodiments, the polynucleotides encode an antigenic peptide that will induce an immune response to a tumor or cancer. Alternatively, the polypeptides encode antigens that induce T cell anergy for use in autoimmune disorders. Still further, the antigen is a pathogenic antigen to induce an immune response against a pathogen such a virus or bacterial pathogen.
PCT No. PCT/FR94/00780 Sec. 371 Date Dec. 28, 1995 Sec. 102(e) Date Dec. 28, 1995 PCT Filed Jun. 28, 1994 PCT Pub. No. WO95/01431 PCT Pub. Date Jan. 12, 1995The present invention relates to a family of peptides known as xenoxins, wherein the representative members can be isolated from the secretions from the skin of Xenopus laevis. The present invention also relates to the members of the peptide family as well as to methods for preparing them and to the DNA sequences encoding them. The invention further relates to pharmaceutical compositions containing said xenoxins as well as to diagnostic kits containing xenoxins or containing anti-xenoxin antibodies.
INTRODUCTION: This study aimed to test whether text messages prompting women with breast cancer to perform motor imagery would increase self-report Physical Activity (PA) duration using a randomized parallel trial design.
METHOD: 52 participants were assigned to a Placebo, Imagery first or Imagery second group. The groups were exposed to two counterbalanced conditions: no morning text message or morning text message for 4 weeks. In the morning text message condition, the Imagery first and Imagery second groups received a message with the instruction to imagine realizing an aerobic exercise of their choice whereas the Placebo group received a placebo message, 3 days per week. In addition, all participants received an evening text message: "Did you do your cardio today? If yes, what did you do?". Before, during and after the experimental session the participants fulfilled questionnaires assessing weekly PA, motivation to perform PA, self-efficacy and fatigue.
RESULTS: Participants in the Imagery groups reported significantly more weekly minutes of aerobic exercise and self-efficacy scores in the imagery morning message condition compared with the no morning message condition. The imagery groups reported significantly higher PA than participants in the Placebo group when the latter received the neutral morning message.
CONCLUSIONS/IMPLICATIONS: Text message can be effective in increasing minutes of aerobic exercise and self-efficacy in women with breast cancer.
A computer-implemented method performed by a central system for establishing control ranges for a plurality of remote medical analyzer devices is disclosed. The method comprises obtaining a plurality of measurement results associated with a plurality of quality control (QC) measurements performed by a plurality of medical analyzer devices on a set of predefined QC samples. Each QC sample is associated with a predefined target range and wherein each medical analyzer device is associated with a peer group of medical analyzer devices. The method further comprises determining, for each peer group out of a plurality of peer groups, a peer control range for each predefined QC sample by processing the plurality of measurement results of the peer group in view of the associated target range. Furthermore, the method comprises determining, for each medical analyzer device, a control range for each predefined QC sample based on the determined peer control range of the associated peer group. The method further comprises transmitting, to a device for managing at least one medical analyzer device, data indicative of the determined control ranges for the set of predefined QC samples for the at least one medical analyzer device.